Tuesday, January 24, 2012

Veracyte thyroid test gets boost with Genzyme deal

When biotech drug developer Genzyme Corp. said Friday that it will market a thyroid nodule analysis test, South San Francisco-based Veracyte Inc. got a big boost.
Although terms of the deal were not disclosed, Genzyme’s promotion means the Afirma test from Veracyte will get higher visibility. Genzyme, which was bought last year by French drug developer Sanofi, markets Thyrogen for patients with well-differentiated thyroid cancer.
After a Johns Hopkins study last year found that Afirma’s use could save money for the health care system, I spoke with Veracyte co-founder and CEO Bonnie Anderson.

No comments:

Post a Comment